BGPT: Paper Review: HDAC11 Deacetylates BRAF to Regulate Kinase Activity and Cell Proliferation.

Fuel Your Discoveries

Low confidence. Please provide more context.

Quick Explanation Copied

I can’t perform a fully accurate, evidence-anchored review of the specific paper “HDAC11 Deacetylates BRAF to Regulate Kinase Activity and Cell Proliferation” because the prompt does **not** include the paper’s DOI/full text excerpt, figures, author list, or methods/results needed to verify claims. What I *can* do right now is (i) ground the **biological plausibility** of an HDAC11–kinase/proliferation link using nearby, well-evidenced HDAC11 literature (including HDAC11’s fatty-deacylase biology and catalytic tool compounds) and (ii) give you a **rigorous falsification checklist** for the BRAF claim once you paste the paper’s relevant sections.

Long Explanation

Paper review status (critical + evidence-based)

The prompt does not include the target paper’s DOI, abstract, figures, or experimental details. Without those, I cannot verify what was actually measured for “HDAC11 Deacetylates BRAF…” (e.g., whether the authors truly showed deacetylation versus defatty-acylation, direct BRAF post-translational modification, kinase assays, or proliferation phenotypes).

If you paste any of: (1) DOI + methods/results text, (2) the figure panels, or (3) the key Western/enzymology/RNA/proliferation readouts, I can redo this review precisely and cite the paper.

1) What is already well-supported about HDAC11 (to judge biological plausibility)

HDAC11’s hallmark chemistry is efficient defatty-acylase activity (often demyristoylation/demyristoyl-lysine), and many sources describe limited or variable “classical deacetylase” activity relative to fatty deacylation.
Selective HDAC11 inhibitors exist and can produce cellular target engagement readouts (e.g., SHMT2-related fatty acylation changes), which is critical because nonspecific HDAC/SIRT perturbations can masquerade as “HDAC11 effects.”
HDAC11 can control diverse cellular outcomes including RNA splicing via reversible lysine myristoylation of SF3B2 (K10), demonstrating that HDAC11-regulated pathways can be mechanistically specific rather than merely “epigenetic noise.”

Implication for the BRAF paper claim: if the paper truly states “HDAC11 deacetylates BRAF,” the strongest burden is to show direct enzymatic activity on the BRAF residue(s) in vitro and identify the modification state change on BRAF in cells. Given HDAC11’s well-supported fatty-deacylase bias, “deacetylation” claims should be scrutinized—many groups use mechanistic vocabulary loosely unless modification mass-spec/validated antibodies are shown.

2) Evidence checklist to validate (or falsify) “HDAC11 → BRAF → proliferation”

A. Chemical mechanism (directness)

Direct modification: Show BRAF modification state (e.g., acetylation or fatty-acylation state) on specific residue(s> upon HDAC11 perturbation (KD/KO and selective inhibitor), ideally using mass spectrometry or residue-specific immunochemistry with validated controls.
Enzymology: Demonstrate HDAC11 catalytic activity against a BRAF-derived peptide/substrate containing the claimed residue(s), showing dose-dependent kinetics and catalytic-dead HDAC11 loss of function.
Residue specificity controls: show that mutating the candidate residue blocks the modification change (and rescues kinase activity).

B. Signaling causality (BRAF kinase readouts)

Kinase activity: Provide quantitative kinase signaling outputs (e.g., phospho-ERK/MEK or direct in vitro kinase readouts) that track with HDAC11 perturbation and with BRAF residue mutation.
Epistasis: If HDAC11 acts through BRAF, then BRAF inhibition or BRAF residue mutation should abolish HDAC11 effects on downstream phosphorylation and proliferation.

C. Cell phenotype specificity (avoid off-target inference)

Selective tool reliance: Prefer HDAC11-selective inhibitors and/or orthogonal genetic approaches; nonspecific HDAC inhibitors can change many pathways and mimic “BRAF regulation.”
Multiple cellular contexts: Use at least two relevant models (and ideally BRAF-mutant backgrounds where BRAF biology is central), showing consistent direction of effects.
Dead-catalyst rescue: Catalytic-dead HDAC11 expression should fail to reproduce HDAC11 effects if the mechanism is enzymatic.

Known blind spot: HDAC11’s best-established substrates/readouts are often fatty-acylation/multimeric complex-associated events (e.g., SHMT2-related), so “BRAF acetylation” would require unusually strong direct evidence.

3) Quantitative visualizations from nearby HDAC11 tool-compound data (raw extracted points)

The BRAF paper’s strength depends heavily on inhibitor selectivity and on mechanistic readouts. To help you evaluate “how selective is HDAC11 perturbation?”, here are published IC50 values for HDAC11 inhibitors SIS7/SIS17 and FT895 using acyl-lysine peptide substrates.

Inhibitor IC50 table (only values explicitly provided)

Inhibitor	Substrate used	Reported IC50 (μM)	Evidence notes (from extracted summary)
SIS7	myristoyl-H3K9 peptide	0.91	IC50 in micromolar/sub-micromolar range; SAR-optimized
SIS17	myristoyl-H3K9 peptide	0.83	thiophene electron-rich ring; highly potent
FT895	myristoyl-H3K9 peptide	0.74	reference HDAC11 inhibitor; less selective than SIS7/SIS17

Interpretation caution: IC50 comparisons require the same substrate/assay conditions and should be paired with selectivity profiling; otherwise, “HDAC11 potency” may not equal “HDAC11 specificity.”

4) How I would judge the BRAF paper’s claims once you provide it

Terminology audit: ensure the paper’s “deacetylates BRAF” matches the actual chemistry/assay (e.g., acetyl-lysine readouts vs myristoylation/defatty-acylation readouts). HDAC11’s best-supported functional class is defatty-acylation.
Mechanistic sufficiency: catalytic-dead rescue + BRAF residue mutant phenocopy/rescue + upstream/downstream epistasis.
Specificity controls: non-target deacetylases/HDACs unaffected, or at least orthogonal inhibitors/genetics to show the phenotype requires HDAC11 enzymatic activity.
Phenotype robustness: at least two independent cellular contexts and multiple time points; ensure proliferation changes aren’t secondary to global stress from overexpression/knockdown artifacts.

5) What I need from you to complete a true “paper review”

Paste one of the following:

DOI / PubMed link
Abstract + Methods + Key Figure captions
Or just the figure(s) that claim HDAC11 modifies BRAF and that show kinase activity/proliferation effects

Feedback:

Updated: April 04, 2026